APX-343A

· Aptabio Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for APX-343A, covering 2025-11-19 to 2025-11-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors [Phase 1]

See pricing